SG Americas Securities LLC Sells 6,103 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

SG Americas Securities LLC reduced its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 25.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,834 shares of the company’s stock after selling 6,103 shares during the period. SG Americas Securities LLC’s holdings in Cardiff Oncology were worth $77,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CRDF. HB Wealth Management LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth approximately $105,000. Barclays PLC raised its holdings in shares of Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock valued at $141,000 after purchasing an additional 39,542 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of Cardiff Oncology by 44.3% in the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock valued at $321,000 after purchasing an additional 36,947 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Cardiff Oncology by 11.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock valued at $324,000 after purchasing an additional 12,503 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Cardiff Oncology by 432.7% in the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock opened at $4.15 on Friday. The firm has a 50-day moving average of $3.90 and a 200-day moving average of $3.06. The stock has a market cap of $212.19 million, a PE ratio of -4.41 and a beta of 1.77. Cardiff Oncology, Inc. has a 52-week low of $1.65 and a 52-week high of $6.42.

Wall Street Analyst Weigh In

CRDF has been the topic of a number of recent research reports. HC Wainwright lowered their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Piper Sandler lifted their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace purchased 350,115 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.80% of the stock is owned by insiders.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.